| abstract |
The purpose of the present invention is to identify a mutation that can serve as an indicator for predicting the efficacy of treatment of stomach cancer or another such cancer by a drug; provide a means for detecting the mutation; and provide means for identifying, on the basis of on this mutation, a cancer patient or subject at risk for cancer in whom a drug that targets a gene having this mutation or a protein encoded thereby will have a therapeutic effect. A method for detecting a gene fusion which is a mutation (driver mutation) responsible for cancer, said method including a step for detecting, in a sample isolated from a subject, any fusion polynucleotide among ATG3-EPHB1 fusion polynucleotide, TNIK-RNF123 fusion polynucleotide, or SLC12A2-NRG2 fusion polynucleotide, or a polypeptide encoded by this fusion polynucleotide. |